Tesamorelin Peptide: What It Is, How It Works, and What the Evidence Shows

Tesamorelin is a synthetic growth hormone-releasing hormone analog that tells the pituitary gland to release more of the body’s own growth hormone. It is FDA-approved as Egrifta/EGRIFTA WR to reduce excess visceral abdominal fat in adults with HIV-associated lipodystrophy, and other uses are off-label.

What is tesamorelin?

Tesamorelin is a modified version of human growth hormone-releasing hormone, often shortened to GHRH. GHRH is the brain signal that tells pituitary somatotrophs, a type of pituitary cell, to release growth hormone in pulses.

The brand medication Egrifta and EGRIFTA WR contains tesamorelin. The FDA-approved indication is to reduce excess visceral abdominal fat in adults with HIV-associated lipodystrophy, not general weight loss or anti-aging use 1.

A stabilized GHRH analog

Natural GHRH breaks down quickly in the body. Tesamorelin is changed at the N-terminal end so it lasts long enough to act as a medication while still targeting the GHRH receptor 1.

That makes tesamorelin different from growth hormone itself. Instead of supplying growth hormone from outside the body, it asks the pituitary to release growth hormone through the body’s own signaling system 1.

Brand name Egrifta and its FDA-approved indication

The FDA label is narrow: tesamorelin is approved for excess visceral abdominal fat in adults with HIV-associated lipodystrophy. Visceral adipose tissue, or VAT, is the deeper fat around the organs, not the pinchable fat under the skin 1.

This matters because many online discussions use tesamorelin as a body-composition or longevity peptide. Those uses are off-label. Off-label use can be medically reasonable in some settings, but it needs a clinician who can weigh risks, labs, and goals.

How does tesamorelin work in the body?

Tesamorelin binds the GHRH receptor on the pituitary gland, which increases growth hormone release and raises insulin-like growth factor 1, or IGF-1. The key clinical idea is that GH and IGF-1 signaling can shift how the body handles fat, especially deeper abdominal fat.

Binding the GHRH receptor on the pituitary

The pituitary gland sits at the base of the brain. Tesamorelin activates GHRH receptors on pituitary somatotrophs, leading to more growth hormone secretion 1.

This is why tesamorelin is often grouped with GHRH analog peptides. Sermorelin, which Chia offers as injection, nasal spray, and tablets, is also a GHRH analog, but it is a separate medication from tesamorelin.

Pulsatile GH release and IGF-1

Growth hormone is normally released in pulses, not as a flat signal all day. Tesamorelin works upstream of growth hormone, so the body still uses the pituitary as the release point 1.

As GH signaling rises, the liver and other tissues make more IGF-1. In the FDA label, IGF-1 monitoring is important because some patients develop levels above the normal range 1.

Why visceral fat may respond

Visceral fat is metabolically active. Growth hormone signaling can increase lipolysis, which is the breakdown of stored fat, and may affect fat stored around organs differently than fat under the skin 2.

That does not mean tesamorelin is a general weight-loss drug. In trials, the main measured change was visceral adipose tissue on imaging, while scale weight did not always move in the same way 2.

What are the clinically studied benefits of tesamorelin?

Tesamorelin has its strongest human evidence in HIV-associated lipodystrophy, where imaging studies measured changes in visceral abdominal fat over 26 weeks. Other studies have looked at liver fat, muscle quality, and cognition, but those uses remain outside the FDA-approved indication.

Visceral adipose tissue reduction

In a 26-week randomized trial published in the New England Journal of Medicine, Falutz and colleagues studied tesamorelin in adults with HIV and abdominal fat accumulation. Tesamorelin reduced visceral adipose tissue compared with placebo, and individual results varied 2.

A follow-up extension found that people who stayed on tesamorelin maintained visceral fat reductions, while those switched to placebo after initial treatment regained visceral fat toward baseline. That is an important limit: effects may fade after stopping 3.

Effects on liver fat and metabolic markers

Tesamorelin has also been studied for liver fat in people with HIV. In a randomized clinical trial, Stanley and colleagues found that tesamorelin reduced liver fat and slowed progression of liver fibrosis markers compared with placebo, while also requiring glucose and IGF-1 monitoring 4.

This is not the same as saying tesamorelin treats fatty liver disease in the general population. The trial population and goals matter, and the FDA-approved indication remains HIV-associated lipodystrophy 1.

Skeletal muscle area and density

A body-composition analysis in adults with HIV and abdominal fat accumulation found that tesamorelin was associated with changes in skeletal muscle area and density on CT imaging. The authors studied these as imaging outcomes, not as proof of better strength or function 5.

That distinction matters. A scan can show muscle area or density, but daily function, strength, pain, and injury risk are separate outcomes that need their own studies.

Cognitive signals in older adults

Growth hormone-releasing hormone has been studied in older adults for cognitive outcomes. In a randomized trial in JAMA Internal Medicine, GHRH administration improved some cognitive measures in healthy older adults and adults with mild cognitive impairment, but this was not a tesamorelin approval study 6.

The honest take: GH-axis peptides are biologically interesting, but cognition is not an approved tesamorelin use. Benefits and risks should be discussed with a clinician, especially because GH and IGF-1 signaling can affect fluid retention, glucose, and tissue growth signals 1.

How long does tesamorelin take to reduce belly fat?

Tesamorelin is not an overnight belly-fat medication. In the main HIV lipodystrophy trials, the key imaging endpoint was measured at 26 weeks, and some patients may notice waist or fit changes earlier than imaging-confirmed visceral fat changes.

Clinical trials used CT scans to measure visceral adipose tissue, which is more precise than a tape measure. In the 26-week trial, tesamorelin reduced visceral adipose tissue compared with placebo, but the result was measured across a study group, not promised for every person 2.

The extension data are just as important. When tesamorelin was stopped and participants switched to placebo, visceral fat tended to return toward baseline, which suggests ongoing treatment may be needed to maintain the studied effect 3.

What is the standard tesamorelin dosage and how is it given?

The FDA label for EGRIFTA WR describes 1.4 mg injected subcutaneously once daily. Older Egrifta labeling and pivotal trials used 2 mg once daily; dose details should be read as label or study facts, not instructions for self-treatment 1, 2.

Reconstitution and injection sites

The FDA label describes tesamorelin as a subcutaneous injection, meaning it is injected under the skin. The label includes preparation and administration steps for the approved product, including use after reconstitution and rotation of injection sites 1.

Why dosing must be provider-guided

Tesamorelin affects GH and IGF-1, and the label warns about glucose intolerance, fluid retention, hypersensitivity, and possible effects on active malignancy risk. That is why dosing and monitoring belong with a licensed clinician, not a no-prescription peptide vendor 1.

What are the side effects and safety considerations?

Tesamorelin can cause injection-site reactions, joint pain, limb pain, swelling, muscle aches, and numbness or tingling. The label also highlights glucose changes, IGF-1 elevation, hypersensitivity, pregnancy risk, and concerns in people with active malignancy 1.

• Common reported effects include injection-site redness, itching, pain, bruising, swelling, arthralgia, and extremity pain 1.
• Tesamorelin can increase IGF-1, so the FDA label recommends monitoring IGF-1 and considering discontinuation when levels remain high 1.
• Glucose can worsen in some people. The label advises glucose monitoring before and during treatment 1.
• Tesamorelin is contraindicated in pregnancy, in people with active malignancy, in those with disruption of the hypothalamic-pituitary axis, and in people with known hypersensitivity to tesamorelin or mannitol 1.

This is also why access matters. A licensed provider and a regulated pharmacy path are very different from buying a vial labeled “for research use only” without a prescription, quality controls, or lab monitoring.

How does tesamorelin compare with sermorelin, CJC-1295/ipamorelin, and GLP-1s?

Tesamorelin is not the same as Ozempic, semaglutide, tirzepatide, or a GLP-1 medication. It works through the GH and IGF-1 pathway, while GLP-1 and dual incretin medicines work mainly through appetite, insulin, glucagon, and stomach-emptying signals 7, 8.

If your real question is “what helps with weight and appetite,” tesamorelin may not be the right comparison. GLP-1-based care, including compounded semaglutide and compounded tirzepatide, is built around metabolic and appetite pathways, not GH-axis signaling 7, 8.

If your real question is “what supports the GH axis,” then tesamorelin is closer to sermorelin than to a GLP-1. At Chia, sermorelin is the adjacent medication we offer, available as injection, nasal spray, and tablets when clinically appropriate.

Was tesamorelin banned?

Tesamorelin is not broadly “banned” as a medication. It is FDA-approved for a specific medical use, but it is prohibited in competitive sport under the World Anti-Doping Agency’s peptide hormones and growth factors category 1, 9.

That distinction is important. A drug can be legally prescribed for a medical indication and still be banned for performance use in sport. Athletes should check the current WADA list and their sport’s rules before using any GH-axis agent 9.

Tesamorelin is also different from the group of some longevity peptides currently under FDA compounding review, with PCAC scheduled to discuss inclusion on the 503A Bulks List on July 23-24, 2026. For the latest regulatory status, use FDA.gov and the current FDA meeting materials 10.

How can you access tesamorelin, and where does Chia fit in?

Chia does not currently offer tesamorelin. For FDA-approved tesamorelin use, access usually means evaluation by a clinician familiar with HIV-associated lipodystrophy and dispensing through an appropriate pharmacy channel for Egrifta or EGRIFTA WR 1.

For off-label questions, the safe path is still clinician-supervised care. Tesamorelin changes GH, IGF-1, glucose, and fluid balance, so it should not be treated like a wellness supplement or bought from no-prescription research-chemical sites 1.

Where Chia fits is adjacent, not identical. We offer sermorelin for GH-axis goals, with injection, nasal spray, and tablet forms. Plans currently start at $199/month for sermorelin injection, and all prescriptions require a licensed provider’s review.

For weight-related goals, Chia offers compounded semaglutide injection, with plans currently starting at $249/month, and compounded tirzepatide tablets or injection, with plans currently starting at $249/month for tablets and $299/month for injection. Microdosing plans are available for semaglutide and tirzepatide where clinically appropriate.

We also offer adjacent longevity protocols, including Foundation Longevity, which combines sermorelin injection, NAD+ injection, and glutathione injection, and Weight + Energy, which combines NAD+ injection with a choice of GLP-1.

Chia care is 100% online: a short health questionnaire, review by a licensed US provider, provider-guided dosing when prescribed, portal messaging, and home delivery from state-licensed 503A compounding pharmacies. A prescription is never guaranteed.

What is the bottom line on tesamorelin peptide therapy?

Tesamorelin is best understood as a focused prescription GHRH analog with a narrow FDA-approved use: reducing excess visceral abdominal fat in adults with HIV-associated lipodystrophy. Its best evidence is not for general weight loss, bodybuilding, or routine anti-aging use.

If your goal is visceral fat tied to HIV-associated lipodystrophy, tesamorelin is a conversation for a clinician who can evaluate indication, contraindications, glucose, IGF-1, and cancer history. If your goal is weight care or GH-axis support, Chia can help evaluate adjacent options we actually offer, but those are different medications with different evidence.

Keep reading

Peptides

Best Peptides for Muscle Growth and Fat Loss: What the Evidence Shows

Peptides

Tesamorelin and Ipamorelin: How the Peptide Combo Works

Peptides

Best Peptides for Muscle Growth: What the Evidence Actually Shows